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http://www.biomedcentral.com/1471-2261/13/30RESEARCH ARTICLE Open AccessLow sex hormone-binding globulin is associated
with hypertension: a cross-sectional study in a
Swedish population
Bledar Daka1, Thord Rosen2, Per Anders Jansson3, Charlotte A Larsson4, Lennart Råstam4 and Ulf Lindblad1*Abstract
Background: The aim of this study was to investigate the association of sex hormone-binding globulin (SHBG) and
hypertension in a Swedish population.
Methods: The study is based on a random sample of a Swedish population of men and women aged 30–74 years
(n=2,816). Total testosterone, oestradiol and SHBG were measured in 2,782 participants. Free androgen index was
then calculated according to the formula FAI=100 × (Total testosterone)/SHBG. Hypertension was diagnosed
according to JNC7.
Results: In men, but not in women, significant association between SHBG and both diastolic (diastolic blood
pressure: β=−0.143 p<0.001) and systolic blood pressure (systolic blood pressure β=−0.114 p<0.001) was found. The
association was still significant after adjusting for age, body mass index (BMI), homeostatic model assessment
insulin resistance (HOMA-IR), triglycerides, high density lipoproteins (HDL) and C-reactive protein (CRP) (diastolic
blood pressure: β=−0.113 p<0.001; systolic blood pressure β=−0.093 p=0.001). An inverse association was observed
between SHBG and hypertension in both men (B=−0.024 p<0.001) and women (B=−0.022 p<0.001). The association
was still significant in women older than 50 years after adjustments for age, BMI, physical activity, CRP and alcohol
consumption (B=−0.014, p=0.008).
Conclusion: In conclusion, these results show a strong association between SHBG and blood pressure independent
of major determinants of high blood pressure. This association might be addressed to direct effects of SHBG in
endothelial cells through the receptor for SHBG. If this is confirmed by other observational and experimental
studies, it might become a new field for the development of therapies for lowering blood pressure.
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Low concentrations of total testosterone in men have previ-
ously been associated with obesity, diabetes mellitus and
hypertension, independent of age [1-6]. Studies in male
rabbit models have shown that castration increases athero-
sclerosis [7]. The effects of testosterone on blood pressure
levels may be explained by at least three factors. Firstly, tes-
tosterone is a vasodilatator in vitro, and in vivo experiments
show a direct vasodilatation effect of testosterone [8].
Secondly, low concentrations of testosterone in men have* Correspondence: ulf.lindblad@allmed.gu.se
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reproduction in any medium, provided the orbeen associated with higher total cholesterol and
LDL-cholesterol and to lower levels of HDL-cholesterol,
and consequently to atherosclerosis and hypertension
[5,9-13]. Thirdly, an increased inflammatory response is
associated with endothelial dysfunction and to an increased
arterial stiffness and hypertension. Several clinical trials of
testosterone replacement therapy in men with testosterone
deficiency have shown a decrease in pro-inflammatory
cytokines [14,15], indicating an immune-modulatory effect
of testosterone. Nevertheless, the use of anabolic steroids
(synthetic derivate of testosterone) is associated with
hypertension [16].
A sizeable fraction of circulating testosterone is bound
to sex hormone-binding globulin (SHBG); however, it isd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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testosterone and several cardiovascular risk factors (athero-
genic lipid profile, type 2 diabetes, obesity) mirrors an effect
of free circulating testosterone, or whether SHBG plays a
more direct role. A recent study by Ding et al. [17] showed
a strong association of SHBG as well as genes controlling
the expression of SHBG with the risk for type 2 diabetes,
but not between free testosterone and type 2 diabetes.
While these results are supported by other authors
[18], the role of SHBG in the development of type 2
diabetes is still subject to discussions and its contribution
to the development of hypertension has to our knowledge
not been investigated at all.
The purpose of this study was therefore to investigate
the association between hypertension and SHBG, in both
men and women in a Swedish population.
Methods
Between 2001 and 2005 a random sample of subjects,
aged 30–74 years residing in two municipalities in
South-western Sweden, were enrolled in the study [19].
All individuals that responded to the study invitation and
gave written and informed consent were included as partic-
ipants if they also contributed with physical examination,
filling in the questionnaire, and by donating venous blood.
Participants were stratified by gender in 5-year age groups.
In Vara, 1,811 participants were enrolled (81% participation
rate), while the survey in Skövde included 1,005 subjects
(70%), with the overall participation rate being 76%. After
exclusion of subjects without successful analyses for SHBG,
2,782 subjects (Men=1,385; Women=1,397) remained
to be analysed.
Medical history, socio-economic and life style factors
Details on the study protocol have been published previ-
ously [19]. Standard questionnaires were used to gain infor-
mation on previous hospitalizations, medication (including
preventive hormonal medication and post menopausal hor-
monal medication), smoking and alcohol habits as well as
leisure time physical activity (LTPA). Standard instruments
were also used for the collection of data on demographic
and socio-economic factors such as social networks, social
stress, and symptoms of anxiety and depression.
LTPA was characterised based on the response of
questionnaire item: ‘How much physical activity do you
engage in during your leisure time?’ [20] The question
referred to the past year and the answer alternatives were:
1. Sedentary leisure time: Reading, TV, stamp collecting or
other sedentary activity; 2. Light LTPA: Walking, cycling
or other physical activity under at least four hours per
week; 3. Moderate LTPA: Running, swimming, tennis, aer-
obic, heavier gardening or similar physical activity during
at least 2 hours a week; and 4. Heavy training or competi-
tive sport: Heavy training or competitions in running,skiing, swimming, football, etc. performed regularly and
several times per week. Smoking habits was defined as
current, former or daily smoking. Alcohol consumption
was assessed by a standardized set of questions on how
many days during the last 30 days had the subjects con-
sumed beer, wine and strong liquor, respectively. Each of
these questions was followed by questions on how many
cans, glasses and/or bottles were normally consumed on
such days. The total gram of alcohol consumed per week
was then calculated by multiplying the number of days of
alcohol drinking with the gram of alcohol that the items
of consumed alcoholic beverage contain [21].
Physical examination
The nurses measured the standard resting blood pressure
twice, one minute apart after five minutes rest with the
subjects in a supine position. (Right brachial artery, arm at
heart level, cuff size adjusted for arm circumference and
reading the pressure at the closest 2 mmHg). The mean
value of the two blood pressure readings was used for
the analyses.
Clinical chemistry
Samples including plasma and serum were drawn after an
overnight fasting and were immediately frozen at −82°C. In
participants without known diabetes mellitus (DM), an
OGTT was performed. Total cholesterol, HDL-cholesterol,
LDL-cholesterol and S-triglycerides were analysed using
standard procedures.
Total testosterone was analysed with kits Beckman
Coulter 2003, 386982A (CV=7-8%) and estradiol (CV=9-
15%) and sex hormone-binding globulin (SHBG) (CV=5%)
were analysed by kits Siemens Immulite 2000XPi [22].
These analyses were conducted in Malmö (Skåne University
Hospital) and at Unilabs at Skaraborg Hospital in Skövde
with results expressed in nmol/L. In 19 cases, the SHBG
concentrations were reported to be higher than 180 nmol/L;
however, they were not further specified. Thus, we assumed
those to be 180 nmol/L. We calculated a free androgen
index (FAI) for the estimation of free testosterone by the
formula FAI=100xTotal testosterone/SHBG [23].
Phenotypic characterisation
Impaired fasting glucose, impaired glucose tolerance and
diabetes mellitus were defined according to the WHO
criteria [24]. Hypertension was defined according to the
JNC 7 criteria [25]. BMI was calculated using the
formula BMI=weight(kg)/high(m)2. Insulin resistance
was estimated using the homeostatic model assessment
for insulin resistance (HOMA-IR) [26].
Ethical considerations
All participants gave signed informed consent before
being enrolled in the study, and the Ethical Committee
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the study.
Statistics
Standard methods were used for descriptive statistics. The
association between SHBG, sex hormones and blood pres-
sure was investigated in simple and multiple linear regres-
sion models after exclusion of subjects treated with blood
pressure lowering drugs. Logistic regression analyses were
performed to estimate the association between hyperten-
sion and sex hormones-SHBG. Associations were expressed
as regression coefficients (B) and odds ratios (OR), respect-
ively, both with 95% confidence intervals (CI). General lin-
ear models were used to estimate differences (CI) between
continuous variables. Theoretical multivariate models were
used to estimate the role of possible confounders on the
investigated association. All analyses were two-sided and
the significance was accepted if p<0.05. All analyses were
performed using SPSS Statistics for Mac. In order to evalu-
ate the strength of the association for each possible risk
factors of hypertension, we standardised the variables in
consideration by the formula SV=V/SD, where SV is the
standardised variable. V is the value of the variable and SD
is the standard deviation. We then ranked their association
with hypertension by the regression coefficient β in the
logistic regression analyses.
Results
The characteristics of the study population are presented
in Table 1. In men, the SHBG increased linearly with ageTable 1 Phenotypical characterisation of sex hormone-bindin
Men 1,385
Quartiles for SHBG
All Q1 Q2 Q3 Q4
SHBG 33±14 17.8 26.7 35.1 50.8
Age 47.8±11.8 42.2 45.6 48.8 54.4
BMI 26.9±3.6 28.9 27.3 26.5 24.9
Fasting insulin 6.7±5.2 8.9 7.0 6.2 4.9
Fasting glucose 5.5±1.1 5.8 5.7 5.5 5.4
HOMA-IR 1.7±1.6 2.3 1.8 1.5 1.1
Hs-CRP 2.4±5.8 3.0 2.3 1.9 3.3
LDL 3.4±0.9 3.4 3.4 3.4 3.3
HDL 1.2±0.3 1.1 1.2 1.2 1.3
Triglycerides 1.5±0.9 1.9 1.5 1.3 1.1
Systolic BP 123±16 126 124 123 123
Diastolic BP 72±10 73.8 71.7 71.8 70.6
Total Testosterone 14.3±4.4 11.2 13.4 15.2 17.5
Oestradiol 127±56 125 128 124 132
FAI 48.5±17.3 64.5 50.5 43.4 35.3
SHBG= sex hormone-binding globulin, Q1 is the lowest quartile and Q4 is the highe
resistance, hs-CRP=high sensitive c-reactive protein, LDL=low density lipoprotein, H
General linear models to estimate mean values and differences between quartiles wbut in women there was a u-shaped association between
age and SHBG. A strong negative association between
SHBG and BMI, fasting plasma glucose, HOMA-IR and
TG was found in both men and women and the same
was true for systolic and diastolic blood pressure. SHBG
was strongly associated with total testosterone in men
and oestradiol in women.
In our population 271 (10%) individuals were under
treatment for hypertension. The association between
SHBG and blood pressure after excluding subjects on
medication for hypertension is presented in Table 2. In
men, significant association between SHBG and both
diastolic (diastolic blood pressure: β=−0.143 p<0.001) and
systolic blood pressure (systolic blood pressure β=−0.114
p<0.001) was found. The association was still significant
after adjusting for age, BMI, HOMA-IR, triglycerides,
HDL and CRP (diastolic blood pressure: β=−0.113
p<0.001; systolic blood pressure β=−0.093 p=0.001). In
women, no association between SHBG and systolic and
diastolic blood pressure, respectively, was found.
Age-adjusted differences of SHBG concentrations in dif-
ferent blood pressure categories in accordance with JNC7
are presented in Figure 1. In men, SHBG decreased signifi-
cantly with the severity of high blood pressure. In women,
however, the SHBG was almost constant in categories NT
and prehypertension1-3. Hypertensive women had signifi-
cantly lower concentrations of SHBG when compared with
all other categories (p<0.001).
The associations between quartiles of SHBG and
hypertension are presented in Table 3 for both men andg globulin in a Swedish population of men and women
Women 1,397
p-trend Quartiles for SHBG p-trend
All Q1 Q2 Q3 Q4
55±31 26.2 41.1 55.6 92.6
<0.001 47.7±11.7 46.9 47.3 49.0 47.7 0.033
<0.001 26.8±5.3 30.1 27.2 26.5 24.9 <0.001
<0.001 6.2±4.4 8.5 6.2 5.1 4.7 <0.001
<0.001 5.3±1.1 5.7 5.4 5.1 5.1 <0.001
<0.001 1.5±1.3 2.2 1.5 1.2 1.1 <0.001
0.038 2.7±4.6 4.1 2.5 2.2 2.3 0.097
0.327 3.1±0.9 3.2 3.1 3.2 3.2 0.287
<0.001 1.4±0.3 1.2 1.4 1.5 1.5 <0.001
<0.001 1.2±0.6 1.4 1.1 1.0 1.1 0.004
<0.001 119±18 123 118 117 119 0.008
<0.001 69±10 70.0 68.4 67.8 68.2 0.007
<0.001 1.3±1.3 1.3 1.2 1.2 1.3 0.853
0.026 320±396 255 328 337 363 <0.001
<0.001 3.1±5.8 5.7 2.9 2.4 1.4 <0.001
st. BMI=Body mass index, HOMA-IR= homeostatic model assessment insulin
DL=high density protein, BP= blood pressure, FAI=free androgen index.
ere used. The significance was estimated with p-value.
Table 2 The association between total testosterone, SHBG, oestradiol, free testosterone, respectively, and blood
pressure in men and women
Men 1,255 Women 1,259
Systolic blood pressure Diastolic blood pressure Systolic blood pressure Diastolic blood pressure
β p β P β p β P
Model 1 Adjusted for age
Total testosterone -0.136 <0.001 -0.121 <0.001 -0.011 0.470 -0.013 0.638
Sex hormone-binding globulin -0.114 <0.001 -0.143 <0.001 -0.031 0.193 -0.055 0.041
Oestradiol -0.014 0.560 0.022 0.408 -0.035 0.144 -0.057 0.036
Free testosterone -0.051 0.119 -0.051 0.154 0.009 0.698 0.016 0.574
Model 2 Adjusted for age and BMI
Total testosterone -0.114 <0.001 -0.098 0.001 -0.008 0.873 -0.018 0.576
Sex hormone-binding globulin -0.083 0.005 -0.117 <0.001 0.020 0.685 -0.018 0.610
Oestradiol -0.019 0.440 0.017 0.530 -0.036 0.121 -0.025 0.461
Free testosterone -0.039 0.243 -0.035 0.328 -0.016 0.570 -0.001 0.988
Model 3 Adjusted for age, BMI, TG, HDL and CRP
Total testosterone -0.111 <0.001 -0.089 0.002 -0.002 0.932 -0.014 0.468
Sex hormone-binding globulin -0.078 0.009 -0.105 0.001 0.043 0.146 0.004 0.908
Oestradiol -0.026 0.295 0.000 0.999 -0.008 0.768 -0.020 0.556
Free testosterone -0.034 0.348 -0.033 0.363 -0.019 0.487 -0.006 0.855
Model 4 Adjusted for age, HOMA-IR, Tg, HDL and CRP
Total testosterone -0.123 <0.001 -0.097 0.001 0.005 0.846 -0.008 0.814
Sex hormone-binding globulin -0.093 0.001 -0.113 <0.001 0.041 0.166 0.013 0.718
Oestradiol -0.028 0.277 0.000 0.994 -0.004 0.902 -0.017 0.611
Free testosterone -0.035 0.307 -0.032 0.878 -0.014 0.620 -0.005 0.876
BMI: Body mass index, Tg: triglycerides, HOMA-IR: homeostatic model assessment insulin resistance, HDL: high density lipoprotein, CRP: c-reactive protein,
β: regressions coefficient, p: p value. Linear regression analysis is used to investigate the association between hormonal levels and blood pressure. All subjects





















p for trend <0.001 p for trend <0.001
Figure 1 Comparison of serum concentrations of sex hormone-binding globulin (y-axis) between different blood pressure categories.
JNC7 blood pressure categories; Opt=normal optimal BP <120/80 mm Hg, Nor= normal BP <130/85 mm Hg, Hnor= normal high BP <140/90 mm Hg,
Unst= unstable blood pressure Hypertension was defined as known documented diagnosis for high blood pressure, or by three consecutive BP
reading ≥140/90 mm Hg (systolic and/or diastolic). When the BP exceeded these limits only once or twice the BP was categorized as unstable.
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Table 3 Multivariate analyses of OR for hypertension associated with quartiles of sex hormone-binding globulin in
women and men, respectively
Men OR CI P Women OR CI P
Model 1 Age adjusted OR for HYPERTENSION
All Q 1 vs 4 2.2 1.24-3.75 0.007 All 4.2 2.45-7.06 <0.001
Q 2 vs 4 1.7 1.05-2.78 0.031 2.3 1.31-3.91 0.004
Q 3 vs 4 1.2 0.72-1.82 0.549 1.9 1.12-3.26 0.017
<50 y Q 1 vs 4 1.9 0.76-4.68 0.174 <50 y 2.8 1.14-7.22 0.025
Q 2 vs 4 1.6 0.61-4.24 0.333 1.7 0.61-4.49 0.317
Q 3 vs 4 0.7 0.25-2.18 0.582 1.6 0.53-4.98 0.403
>50 y Q 1 vs 4 2.1 0.99-4.66 0.053 ≥50 y 4.8 2.61-8.88 <0.001
Q 2 vs 4 1.6 0.92-2.78 0.095 2.3 1.21-4.22 0.010
Q 3 vs 4 1.2 0.70-1.95 0.546 2.1 1.17-3.82 0.013
Model 2 Age and BMI adjusted OR for hypertension
All Q 1 vs 4 1.5 0.82-2.67 0.193 ≥50 y 3.1 1.54-6.04 0.001
Q 2 vs 4 1.3 0.81-2.22 0.250 1.9 1.00-3.79 0.049
Q 3 vs 4 1.0 0.63-1.61 0.982 2.2 1.20-4.15 0.012
Model 3 Age, BMI, smoking habits, hs-CRP, LDL, triglycerides, and alcohol consumption adjusted
All Q 1 vs 4 1.5 0.78-2.70 0.235 ≥50 y 3.0 1.47-6.33 0.003
Q 2 vs 4 1.4 0.81-2.22 0.217 2.1 1.04-4.09 0.038
Q 3 vs 4 1.0 0.59-1.57 0.867 2.1 1.12-4.04 0.021
Model 4 Age, HOMA-IR, smoking habits, hs-CRP, LDL, triglycerides, and alcohol consumption adjusted
All Q 1 vs 4 1.8 0.96-3.27 0.067 ≥50 y 2.7 1.33-5.60 0.006
Q 2 vs 4 1.4 0.83-2.43 0.202 1.9 0.95-3.67 0.070
Q 3 vs 4 1.1 0.67-1.79 0.721 1.8 0.97-3.41 0.061
BMI: Body mass index, Tg: triglycerides, HOMA-IR: homeostatic model assessment insulin resistance, LDL: Low density lipoprotein, CRP: c-reactive protein,
HRT: hormone replacement therapy, OR: odds ration for hypertension, p: p value. Logistic regression analysis is used to investigate the association between
hormonal levels and hypertension. Possible confounders were taken into consideration in different models stepwise.
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were higher for the lowest quartile (OR=4.2 p<0.001). The
association was different when comparing women under
or over age 50 years (Women under 50 OR=2.8, CI 1.14-
7.22, p=0.025, women over 50 OR=4.8, CI 2.61-8.88,
p<0.001). In women under 50, the association was not sig-
nificant when adjusting for age and BMI. In contrary,
for women over 50, the association remained significant
when we adjusted for age, HOMA-IR, smoking habits,
hs-CRP, LDL, Tg, hormone-replacement therapy and alco-
hol consumption (p-trend=0.05). The association remained
significant even when we included a known history of
stroke and diabetes in the equation (p-trend=0,043).
In men, an association between quartiles of SHBG and
hypertension (OR=2.2 p=0.007) was found. The asso-
ciation was not significant when adjusting for BMI
(Table 3).
In Table 4 we ranked age, HOMA-IR, BMI and SHBG
by regression coefficient in order to evaluate the strength
of the association with hypertension. Age was strongest
associated with hypertension and BMI was second in
both men and women. The association between
SHBG and hypertension was stronger than the associationbetween HOMA-IR (surrogate of insulin resistance) and
hypertension in men but not in women.
The interaction between sex hormones, SHBG and
hypertension was investigated in a logistic regression
model, but no significant interaction was found. The
interaction between age and SHBG in the hypertension
and blood pressure was also investigated with regression
models, but no significant difference was found.
Discussion
In this cross-sectional study, a strong inverse association
between blood pressure and SHBG was observed. Post-
menopausal women with hypertension had significantly
lower SHBG concentrations, and this association was sig-
nificant even after adjusting for major risk factors for hyper-
tension such as age, BMI, diabetes and insulin resistance. In
men, we observed an inverse association between systolic
blood pressure and SHBG. This association was independ-
ent of major confounders. Both these findings indicate that
low concentrations of SHBG may have independent
negative effects in the control of blood pressure.
To our knowledge this is the first study to estimate
the specific role of SHBG in blood pressure control.
Table 4 Association between hypertension and sex hormone-binding globulin when major risk factors for
hypertension are considered
Men β p Exp Women β p Exp
All Age 1.352 <0.001 3.9 1.299 <0.001 3.7
BMI 0.298 0.004 1.3 0.376 0.002 1.5
HOMA-IR 0.060 0.497 1.1 0.347 0.002 1.4
SHBG -0.194 0.061 0.8 -0.297 0.027 0.7
<50 Age 0.619 <0.001 1.9 0.967 <0.001 2.6
BMI 0.298 0.004 1.3 0.532 0.012 1.7
HOMA-IR 0.049 0.497 1.1 0.018 0.927 1.0
SHBG -0.164 0.061 0.8 -0.103 0.698 0.9
≥50 Age 0.882 <0.001 2.4 0.723 <0.001 2.1
BMI 0.298 0.004 1.3 0.382 0.012 1.5
HOMA-IR 0.072 0.491 1.1 0.538 0.001 1.7
SHBG -0.210 0.063 0.8 -0.333 0.033 0.7
BMI: Body mass index, HOMA-IR: homeostatic model assessment insulin resistance, SHBG: sex hormone-binding globulin, β: regressions coefficient, p: p value, Exp:
the odds change for hypertension for increasing with 1 standard deviation of variable. Age, BMI, HOMA-IR are standardised in order to compare the impact in
hypertension. Logistic regression analysis is used to rank the strength of the association. All women with hormonal therapy are excluded from the analyses. Every
considered variable is standardised. The purpose was to rank the strength of the association with hypertension for each variable and the value of β decide the
strength of the association. We standardised the variables in consideration by the formula SV=V/SD, where SV is the standardised variable. V is the value of the
variable and SD is the standard deviation.
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between hypertension and SHBG in men, but very few
in women. The majority of studies, aimed to estimate
the effects of testosterone on blood pressure in men,
provided information about the level of SHBG. This was
done in order to estimate the concentrations of free tes-
tosterone. However, only a few studies have presented
information about the association between SHBG and
hypertension. In a prospective study in men, aimed to
investigate the role of sex hormones in hypertension,
Khaw et al. [5] observed that total testosterone but not
SHBG was associated with hypertension. However, in
accordance with our results, they found an inverse asso-
ciation between SHBG and diastolic blood pressure
adjusted for age. The definition of hypertension in that
study was different from our definition based on JNC7
(160/95 in Rancho Bernard and 140/90 in VSC). A
cross-sectional study in men conducted in Tromsö [27],
which aimed to investigate the association between
testosterone on one hand and hypertension and left
ventricular hypertrophy on the other hand, found an
age-independent association between SHBG and both
systolic and diastolic blood pressure. The association
remained borderline significant for the systolic blood
pressure (p=0,057) even after adjusting for BMI and
alcohol consumption, but for diastolic blood pressure it
was not significant (p=0,370). Significantly lower concen-
trations of SHBG were found in hypertensive men even
after adjusting for age, BMI and SHBG concentrations in
accordance with our results in women [27].
Some gender differences were, however observed in
our study (Figure 1). In accordance with Khaw et al. [5]levels of SHBG decreased in a linear fashion in men
when the blood pressure increased. In contrary in
women the decrease in SHBG were firstly observed when
they had developed hypertension. As the association
between SHBG and hypertension in women was stronger
over the age of 50 we suppose that these gender differences
can at least in part be addressed to the menopause. In a
prospective study including men and post-menopausal
women, Ding et al. [17] observed a predictive value of
SHBG concentrations concerning incident cases of
type 2 diabetes, in both men and women. They
reported an association between hypertension and low
concentrations of SHBG in women in the crude analysis.
However, the authors did not report whether any multi-
variate statistical tests accounting for possible confounders
were computed. Neither was the association between
SHBG and hypertension in males at baseline reported.
We did not found studies comparing the strength of the
association between SHBG and hypertension with other
risk factors for hypertension. In order to compare the
SHBG with other conventional risk factors for hyperten-
sion, we standardized age, BMI, HOMA-IR and SHBG. In
our study a weak association between insulin resistance
and hypertension was observed in men were SHBG had
stronger association with hypertension than HOMA-Ir.
Tot-T but not free testosterone was associated with
hypertension in our population. Testosterone deficiency
has been indicated as a risk factor for obesity and cardio-
vascular diseases. The question as to whether T has a direct
effect on blood vessels remains to be investigated. We can-
not confirm the vasodilatative effects of free testosterone
that were shown by Webb et al. [8]. Our results suggest
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may explain the association between testosterone and blood
pressure, at least partially. A recent study has shown that
SHBG but not testosterone is associated with increasing of
blood pressure [28]. In the matter of diabetes risk,
Lakshman et al. [18] speculate on a modulatory effect of
SHBG that enhances the effects of testosterone. In fact, a
membrane receptor for SHBG is present in uterine endo-
metrial cell membranes, isolated prostatic cell membranes,
human placenta, normal breast, liver and epididymis but
not in striated muscle [29]. This receptor, when activated
after contact with SHBG, can stimulate the production of
c-AMP. It must be emphasized that in a minor study with
men with hypertension it was found a strong association
between SHBG and renin that can be another pathway for
direct effects of SHBG on the control of blood pressure
[30]. Whether this association occurs in the blood vessel
and if it influences the blood pressure remains to be
confirmed by studies of a different design. For example,
experimental studies on mice with knocked gene for SHBG
could help in understanding the functions of the protein,
and determine whether this protein only has carrying
functions or if the functions of the protein are extended
inside the target cells for androgen effect.
In accordance with previous studies, we found a positive
linear association between SHBG and age in men while in
women the association is inverse before 50 years of age
[31,32]. The mechanisms lying behind this gender duality
are not fully understood. Some authors suggest that in
men a decrease of testosterone concentrations due to age
is the cause of increasing SHBG concentrations as testos-
terone is supposed to have an inhibitory effect on SHBG
production. Such an effect does not seem to be determin-
ant in increasing SHBG concentrations in aging men
according to De Ronde et al. [33].
Strengths
This was a large population based study that included both
men and women. Therefore, we could compare the associ-
ation of oestradiol, SHBG and testosterone in both men
and women. The study had a high participation rate of
76%, including a younger middle-aged population. The
diagnosis of hypertension was précised with the trained
nurse. In this large study population, we also had informa-
tion about the medication influencing the blood pressure
that gave us the possibility to exclude subjects with blood
pressure lowering medication or with hormonal medication
that could have influenced the analyses. Blood samples
were collected in the morning, thereby avoiding influences
of circadian changes in the hormonal concentrations.
Limitations
A potential weakness of this study might be the lack of in-
formation with regard to menopausal status. Still, the use of50 years as cut-off point for menopause is supported by
findings from previous studies [34,35]. It should also be
emphasized that as this is a cross-sectional study the
causality between SHBG and hypertension cannot be
established and it is possible that hypertension or associated
factors lead to decreased concentrations of sex hormone-
binding globulin. Another limitation of the study is the low
accuracy of the measurements of testosterone in the low
range of the distribution thus concerns especially women
[36]. Moreover there is a circadian variation of concentra-
tions of testosterone and SHBG which probably dilute our
findings [37].
Conclusion
These results show a strong association between SHBG
and blood pressure independent of the components of
metabolic syndrome and inflammation. This association
might be explained by a direct effect of SHBG in endothe-
lial cells through the receptor for SHBG. If others confirm
this it might become a new field for the development of
therapies for lowering blood pressure.
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